Innoviva (INVA) Current Assets (2010 - 2026)
Innoviva's (INVA) quarterly Current Assets came in at $772.6 million in Q1 2026, up 32.75% YoY from $582.0 million in Q1 2025, and up 6.2% on a QoQ basis from $727.5 million in Q4 2025.
Innoviva (INVA) Current Assets (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Current Assets data on file, last reported at $772.6 million in Q1 2026.
- Quarterly Current Assets rose 32.75% year-over-year to $772.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $772.6 million (up 32.75% YoY) and the FY2025 annual result came in at $727.5 million, up 31.25% from the prior year.
- Current Assets advanced to $772.6 million in Q1 2026, from $727.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $772.6 million in Q1 2026 to a low of $16.9 million in Q3 2025.
- A 5-year average of $364.3 million and a median of $344.2 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets soared 170.02% — and 2024, when it plunged 38.8%.
- Tracing INVA's Current Assets over 5 years: stood at $443.5 million in 2022, then retreated by 22.39% to $344.2 million in 2023, then soared by 61.03% to $554.3 million in 2024, then surged by 31.25% to $727.5 million in 2025, then rose by 6.2% to $772.6 million in 2026.
- The last three Current Assets figures came in at $772.6 million (Q1 2026), $727.5 million (Q4 2025), and $16.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 753.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 753.37 Mn |
| Mar 31, 2026 | 772.62 Mn |
| Dec 31, 2025 | 727.52 Mn |
| Sep 30, 2025 | 16.93 Mn |
| Jun 30, 2025 | 651.78 Mn |
| Mar 31, 2025 | 582.02 Mn |
| Dec 31, 2024 | 554.31 Mn |
| Sep 30, 2024 | 22.39 Mn |
| Jun 30, 2024 | 358.28 Mn |
| Mar 31, 2024 | 311.34 Mn |
| Dec 31, 2023 | 344.22 Mn |
| Sep 30, 2023 | 36.59 Mn |
| Jun 30, 2023 | 323.54 Mn |
| Mar 31, 2023 | 296.45 Mn |
| Dec 31, 2022 | 443.51 Mn |
| Sep 30, 2022 | 33.25 Mn |
| Jun 30, 2022 | 400.33 Mn |
| Mar 31, 2022 | 317.82 Mn |
| Dec 31, 2021 | 313.67 Mn |
| Sep 30, 2021 | 49.75 Mn |